fig2
![Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy](https://image.oaes.cc/0db8cd42-8454-4bd8-877d-fb66f9f0f3ca/4600.fig.2.jpg)
Figure 2. The change in absolute standardized mean difference (ASMD) of the seven clinical characteristics included in the propensity score (PS) in a simulated cohort of 100 tenofovir disoproxil fumarate (TDF)- and 900 entecavir (ETV)-treated simulated patients before and after (A) PS matching and (B) weighting. DM: Diabetes mellitus; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus.